GSK commences phase III study of mepolizumab in severe HES patients

This article was originally published here

GlaxoSmithKline (GSK) has initiated a phase III study of its interleukin 5 (IL-5) antagonist, mepolizumab in hypereosinophilic syndrome (HES) patients.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply